ClinicalTrials.gg
CompletedNCT07937904IBSCOLONCAREUpdated Nov 16, 2026

Probiotic Mixture on Gut Microbiota After Colonscopy in IBS Patients

An interventional study of Probiotic supplementation in Abdominal Pain (AP), Irritable Bowel Disease and Colonoscopy, sponsored by San Carlo di Nancy Hospital. Completed at 1 site in Italy. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by San Carlo di Nancy Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Jul 2025, registered Oct 2026).
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 23 studies in Abdominal Pain with a site in Italy — none open to participants now, none under way, none of them phase 3. Abdominal Pain · Italy.

Enrollment
9th of 17
65 · median 65
Started
2025
the only one that year
No phase
10 of 23
none open now
Registered
23rd of 23
by date

Among the 23 studies in Abdominal Pain with a site in Italy, this one is the 9th largest by enrollment of the 17 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 23rd registered.

Abdominal Pain

388 studies on the registry are indexed under Abdominal Pain; 58 are open to participants now.

Browse Abdominal Pain studies →

Open to participants now

None of the 23 studies in Abdominal Pain with a site in Italy is open now. The open studies under Abdominal Pain, anywhere →

Who these studies take

Of the 33 Abdominal Pain studies recruiting now, 13 (39%) set no upper age limit and 17 (52%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Abdominal Pain with a site in Italy as a file.
02

Study summary

The goal of this open-label, pilot study, was to evaluate the impact of bowel preparation on IBS patients' gut microbiota, their recovery within thirty days, and whether the probiotic mixture administration contained in Lactichoc® altered their recovery from spontaneous resilience, while simultaneously monitoring the course of gastrointestinal symptoms. The primary objective of our study is to evaluate whether the administration of this probiotics modifies the recovery of the intestinal microbiota after colonoscopy preparation in patients with IBS in terms of speed (kinetics) and extent of recovery, compared to the spontaneous recovery observed in the control group. The secondary objective is to evaluate the effectiveness of probiotics in improving gastrointestinal symptoms and quality of life (GIQLI questionnaire) and stool consistency (Bristol scale), in patients with IBS undergoing colonoscopy, compared to an untreated control group.

Read the detailed description

For this study a total of 65 adult patients affected by IBS according to the Rome IV criteria were enrolled. We considered as drop out 4 patients because affected bycolon cancer (2 patients) and Inflammatory bowel disease (IBD) (2 patients). Data of 61 patients were analyzed: 30 were allocated to the Interventional group and 31 to the untreated control group. The cohort comprised 34 women and 25 men (sex not recorded for two patients), with a median age of 55 years (IQR 42-67), available for 49 patients. On the day of colonoscopy, after eligibility had been confirmed and the baseline GIQLI questionnaire collected, all patients underwent standard bowel preparation followed by colonoscopy with air insufflation - the same procedure in both arms, and therefore theperturbation common to the whole cohort. Only at the end of the examination were patientsrandomized, in a simple 1:1 ratio, to group A (probiotic group) or group B (control, without supplement).Patients in group A took two capsules per day of the product, equivalent to a total of 80 billionCFU/day, for ten consecutive days, starting from the day after of the endoscopic procedure. The mixture included eight strains: Bifidobacterium animalis subsp. lactis LA304 and LA804,Bifidobacterium bifidum LA803, Bifidobacterium breve LA805, Lactobacillus acidophilusLA201 and LA807, Lactobacillus gasseri LA806, and Lacticaseibacillus rhamnosus LA801.Group B received no supplementation and served as the control group. Throughout the study, patients in both groups were asked to maintain their usual dietary and physical-activity habit sand to avoid any additional probiotics, prebiotics, postbiotics or antibiotics unless clinically necessary. For each patient we collected a stool sample at three times: the first (T1) upon enrollment, beforeeven starting the preparation for the colonoscopy, so as to photograph the microbiota in its starting state. The second (T2) fourteen days after the colonoscopy and the third (T3) thirty days afterwards. For the purposes of this analysis, T1 represented the pre-colonoscopy baseline, whileT2 and T3 captured the early and later phases of microbiota recovery after bowel preparation, respectively. The laboratory of microbiology performed analysis of the stool samples for the gut microbiota. The results were then presented as relative abundances (%) of individual taxa, organized by health marker (gut barrier, inflammatory status, cardiometabolic marker, and gutbrain axis)along with phyla proportions, a bacterial diversity index, and quartile indices of dysbiosis andbutyrate producers, calculated relative to a healthy reference cohort. For each patient, the Firmicutes/Bacteroidetes ratio was also derived from the phyla proportion. Particular attention was paid to groups involved in short-chain fatty acid production, barrier function, and the gut-brain axis. Gastrointestinal symptoms and quality of life were assessed using the GIQLI (GastrointestinalQuality of Life Index) questionnaire, which provided the data collected and analysed in thepresent study. Stool form was additionally evaluated during the study visits using the Bristolscale as an internal clinical parameter; it was not recorded as a study variable and is therefore notincluded among the analysed outcomes.The GIQLI questionnaire was administered at the three study time points: T1, T2, and T3.

03

Conditions studied

  • Abdominal Pain (AP)
  • Irritable Bowel Disease
  • Colonoscopy
  • Probiotic
  • Gut -Microbiota
  • Gut-brain Axis

Keywords

  • irritable bowel syndrome
  • gut microbiota
  • colonoscopy
  • Bifidobacterium
  • Lactobacillus
  • Firmicutes
  • Short chain fatty acid
  • gut brain axis
  • probiotic
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (subjects >18 years)
  • Indication for colonoscopy
  • Signed
  • Willingness to maintain dietary and exercise habits during the study

Exclusion criteria

Exclusion Criteria:

  • Inflammatory Bowel Disease (IBD)
  • Colorectal cancer Colon surgery
  • Use of antibiotics or probiotics in the previous 15 days
  • Pregnancy
  • Severe liver/renal/cardiac disease
  • to colonoscopy or bowel preparation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
65 participants (actual)

Study arms

  • Experimental
    Experimental: probiotic group

    Probiotic supplementation: 30 patients receive supplementation

    Dietary Supplement: Probiotic supplementation

  • No intervention
    Control group (group B)

    Control group: 31 patients don't receive supplementation

Interventions

  • Dietary supplementProbiotic supplementation

    Patients received probiotics

06

What researchers measure

Primary outcomes

  1. Modification of gut microbiota

    Evaluation of gut microbiota modification after the supplementation with probiotics (after colonoscopy)

    Time frame: at baseline (T0), after 14 days from procedure (T1), and after 30 days (T2)

Secondary outcomes

  1. Gastrointestinal Symptoms in IBS

    The secondary objective is to evaluate the effectiveness of probiotics in improving gastrointestinal symptoms and quality of life (GIQLI questionnaire) in patients with IBS undergoing colonoscopy, compared to an untreated control group at baseline (T0), after 14 days (T1), and after 30 days (T2). GIQLI questionnaire is a validate questionnaire composed by 33 questions , each with 5 answers.

    Time frame: at baseline (T0), after 14 days from procedure (T1), and after 30 days (T2)

07

Study locations

1 site
  • San Carlo Nancy Gvm Research
    Roma, Italy
08

References and documents

Publications

  • Jo HH, Lee MY, Ha SE, Yeom DH, Kim YS. Alteration in gut microbiota after colonoscopy: proposed mechanisms and the role of probiotic interventions. Clin Endosc. 2025 Jan;58(1):25-39. doi: 10.5946/ce.2024.147. Epub 2024 Sep 2. PubMed 39219335 ↗
  • Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020 Oct;5(10):908-917. doi: 10.1016/S2468-1253(20)30217-X. Epub 2020 Jul 20. PubMed 32702295 ↗
  • Finn DR. A metagenomic alpha-diversity index for microbial functional biodiversity. FEMS Microbiol Ecol. 2024 Feb 14;100(3):fiae019. doi: 10.1093/femsec/fiae019. PubMed 38337180 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Mar 2026, 8 months.

Of 86 non-industry interventional studies with no phase under Abdominal Pain, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's 8 months is below that.

Counting every sponsor, half of 102 studies reached it within 12 months; a quarter within 5 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 16, 2026
StartActual
Jul 1, 2025
Primary completionActual
Mar 1, 2026
CompletionActual
Mar 1, 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07937904
Lead sponsor
San Carlo di Nancy Hospital
Responsible party
Veronica Ojetti (Professor Veronica Ojetti, San Carlo di Nancy Hospital) — Principal investigator
First posted
Nov 16, 2026
Start date
Jul 1, 2025
Primary completion
Mar 1, 2026
Completion
Mar 1, 2026
Last update
Nov 16, 2026

Study contacts

Veronica Ojetti
principal investigator · San Carlo di Nancy Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion